Cigna (CI) — customer relationships, concentration risks, and what divestitures tell investors

Cigna is a global managed‑care and insurance company that monetizes through two broad channels: premiums and fees from employer and group health plans and health‑services revenue from Evernorth (pharmacy benefit management, specialty and care services). The business combines high‑frequency, recurring cash flows from employer and government clients with concentrated, high‑dollar service contracts in its pharmacy and care‑services businesses — a mix that drives predictable revenue but leaves the company exposed to a few large customers and to strategic rebalancing of book transfers. For investors, the core trade is between durable premium economics and outsized counterparty concentration in PBM/service contracts. Learn more about how we surface relationship intelligence at https://nullexposure.com/.

Why customer relationships matter for valuation and risk

Cigna’s revenue profile reflects two structural facts that shape valuation and operational risk. First, a meaningful share of revenue comes from group and governmental contracting: the firm reports material revenue from U.S. Federal Government agencies, which accounted for approximately 11% of consolidated revenues in 2024 (15% in 2023, 14% in 2022), providing a base of large, contractually anchored business that supports revenue visibility. Second, the Evernorth segment includes a single pharmacy benefit client that generated roughly 16% of consolidated revenues in 2024, creating concentration risk that can quickly swing margins and free cash flow if commercial terms change.

These excerpts from company filings and segment disclosures support three practical operating signals for investors:

Contracting posture: Cigna operates with a mixture of long‑term group and governmental contracts for health plans and discrete large contracts for PBM and specialty services, implying high revenue visibility for core flows but exposure to individual client renegotiation.
Concentration and criticality: The Evernorth PBM relationship is material — a single client equaled ~16% of consolidated revenue in 2024 — making counterparty outcomes a potential earnings lever. Government contracts are similarly material and provide defensive diversification.
Global scale and segment maturity: The company describes itself as a global health company with established services across pharmacy, medical, behavioral and dental lines; Evernorth represents a mature services business that is strategic to Cigna’s growth profile.

Collectively, these signals point to an operating model that is subscription‑like at the premium level and contract‑intensive at the services level, with risk concentrated where Cigna acts as principal and service provider.

What the public record shows about recent customer movements

Cigna recently moved medical customers through strategic divestitures — a pattern that changes the company’s customer mix and has immediate income‑statement effects. A TradingView news post citing a Zacks write‑up on March 9, 2026, reported that Cigna experienced a decline in medical customers following divestitures to Health Care Services Corporation, and that this reduction was a partial offset to other upside in reported results. (TradingView / Zacks, March 9, 2026).

Health Care Services Corporation: Cigna sold certain medical customers to Health Care Services Corporation, a transaction that reduced Cigna’s book of medical customers and therefore lowered medical‑customer counts year‑over‑year; the move was called out in quarter commentary as a headwind to customer metrics. Source: TradingView news story referencing Zacks (March 9, 2026).

That single relationship item is directly visible in recent reporting and underscores how portfolio reshaping via divestiture can materially and immediately affect customer counts and segment revenue.

How these relationship dynamics translate to investor risks and opportunities

Investors must weigh three dynamics when modeling Cigna going forward:

Earnings sensitivity to customer concentration. The 16% share from a single PBM client in 2024 is a binary risk: contract renewal, pricing pressure, or an exit would move consolidated revenue materially. This is a company‑level signal requiring line‑item attention in scenario analysis.
Stability from government contracts. Government agency revenues (roughly 11% in 2024) offset some commercial cyclicality and provide a base level of utilization and cash flow. Treat these as a defensive element when stress‑testing premiums and membership.
Strategic tradeoffs from portfolio reshaping. The divestiture of medical customers to Health Care Services Corporation shows management is willing to reshape the customer book — improving focus or capital allocation but reducing near‑term scale in some segments. That strategy can improve long‑term margins but causes short‑term revenue volatility.

Key takeaway: model Cigna with concentrated downside tied to PBM client outcomes, tempered by durable employer and government contracts and the upside from improved margins if Evernorth consolidates services profitably.

A short checklist for monitoring the customer franchise

Watch disclosures on the single pharmacy benefit client: contract renewals, term length, and fee basis will drive scenario outcomes for margins. Company filings show the client contributed ~16% of revenue in 2024.
Track government contract awards and renewals and the related revenue run‑rate (company filings show ~11% from U.S. Federal agencies in 2024).
Monitor segment disclosures for Evernorth: any shift from gross to net accounting or principal versus agent treatment could change reported revenue and margin profiles.
Follow M&A/divestiture activity and related customer transfers; the March 2026 note on divestitures to Health Care Services Corporation is an immediate example.

If you need a structured view of counterparty concentration and how it maps to Cigna’s earnings power, explore our platform at https://nullexposure.com/.

Conclusion — positioning for asymmetric outcomes

Cigna blends stable premium revenue with concentrated, high‑value service contracts, producing a classic risk‑return tradeoff: predictable cash flows at the core with outsized sensitivity to a few large service counterparties. The recent divestiture to Health Care Services Corporation reduces customer counts in the medical line and illustrates management’s willingness to reshape the book, which improves strategic clarity but increases near‑term earnings variability. Investors should prioritize contract disclosures, PBM client renewal terms, and government revenue trajectories in their thesis.

For a deeper, relationship‑level assessment and to map client concentration into cash‑flow scenarios, visit https://nullexposure.com/ and review our client‑level exposure tools.